Frozen-thawed Embryo Transfers and Hormone Substitution on Thrombotic Risk Markers (TromboFET)

Horsens Hospital

Status: Active, not recruiting

Conditions: Frozen Embryo Transfer

Treatments: Diagnostic Test: Primary and secondary hemostasis

Study type: Observational

Funder types: Other

Identifiers

NCT04359576

TromboFET

Details and patient eligibility

About

The study focus on the impact of estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in women undertaking assisted reproductive technology treatment (ART).

Full description

The aim is to investigate whether the coagulation is activated in women undergoing estrogen/progesterone substitution during artificial cycle frozen embryo transfer (AC-FET) in assisted reproductive technology treatment (ART). An activation of the coagulation might induce an increased thromboembolic risk in these women. Thus, the present study may lead to improvement of the current treatment protocol for women receiving AC-FET and ultimately prevent thromboembolic complications for woman in fertility treatment.

Enrollment: 50 estimated patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women receiving FET with or without estrogen/progesterone substitution

Exclusion criteria

• Known bleeding disorder
• Indication for thromboprophylaxis during ART treatment
• Treatment with anti-platelet medication including non-steroid-anti-inflammatory drugs (NSAIDs) within the last week
• Donor recipients

Trial design

50 participants in 1 patient group

FET

Description:

Estrogen/progesterone substituted and natural cycles

Treatment:

Diagnostic Test: Primary and secondary hemostasis